VS-01 safe, well tolerated in patients with decompensated cirrhosis

Versantis announced positive results from a phase 1b clinical trial of VS-01 in patients with decompensated cirrhosis.“We are very encouraged by the compelling results from this phase 1b trial, which prove the excellent tolerability profile of VS-01 in a cirrhotic patient population,” Vincent Foster, CEO and co-Founder of Versantis, said in the release. “We look forward to the continued development of this therapy in a phase 2a study starting early 2022 and hope to soon provide a meaningful new treatment option to patients suffering from acute liver diseases, whom todayRead More

Share on facebook
Share on twitter
Share on linkedin